M344 is primarily used in research settings as a selective inhibitor of histone deacetylase 6 (HDAC6). Its main application lies in the study of cellular processes involving protein acetylation, particularly in the context of neurodegenerative diseases and cancer. By selectively targeting HDAC6, M344 helps modulate the acetylation status of α-tubulin and other key proteins, which can influence cell motility, protein aggregation, and stress response pathways. It has been utilized in preclinical models to investigate potential therapeutic strategies for conditions such as Alzheimer's disease, Huntington's disease, and multiple myeloma. Due to its ability to induce apoptosis in cancer cells while sparing normal cells, M344 serves as a valuable tool compound in oncology and neurobiology research.